Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04NTJ
|
|||
| Former ID |
DAP000925
|
|||
| Drug Name |
Glisoxepide
|
|||
| Synonyms |
Glisepin; Glisoxepid; Glisoxepida; Glisoxepidum; Glisoxepida [Spanish]; BS 4231; Bay B 4231; FBB 4231; RP22410; Glisoxepida [INN-Spanish]; Glisoxepide (INN); Glisoxepidum [INN-Latin]; Pro-Diaban; Glisoxepide [INN:BAN:DCF]; N-[2-[4-(azepan-1-ylcarbamoylsulfamoyl)phenyl]ethyl]-5-methyl-1,2-oxazole-3-carboxamide; N-{2-[4-({[(azepan-1-ylamino)carbonyl]amino}sulfonyl)phenyl]ethyl}-5-methylisoxazole-3-carboxamide; 1-(Hexahydro-1H-azepin-1-yl)-3-((p-(2-(5-methyl-3-isoxazolecarboxamido)ethyl)phenyl)sulfonyl)urea
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Non-insulin dependent diabetes [ICD-11: 5A11] | Approved | [1], [2] | |
| Therapeutic Class |
Hypoglycemic Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H27N5O5S
|
|||
| Canonical SMILES |
CC1=CC(=NO1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NN3CCCCCC3
|
|||
| InChI |
1S/C20H27N5O5S/c1-15-14-18(23-30-15)19(26)21-11-10-16-6-8-17(9-7-16)31(28,29)24-20(27)22-25-12-4-2-3-5-13-25/h6-9,14H,2-5,10-13H2,1H3,(H,21,26)(H2,22,24,27)
|
|||
| InChIKey |
ZKUDBRCEOBOWLF-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 25046-79-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
8172825, 15478163, 29215430, 34674787, 46508780, 48416056, 49987582, 51091457, 57311407, 75725261, 104314493, 127346563, 127346564, 134338201, 134997083, 136074034, 137006664, 139955826, 144205252, 160708863, 160964607, 164841971, 176246077, 179225782, 198959702, 215784432, 223532541, 226432748, 242326209
|
|||
| ChEBI ID |
CHEBI:135731
|
|||
| SuperDrug ATC ID |
A10BB11
|
|||
| SuperDrug CAS ID |
cas=025046791
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Inward rectifier potassium channel Kir1.2 (KCNJ10) | Target Info | Blocker | [1] |
| KEGG Pathway | Gastric acid secretion | |||
| Reactome | Activation of G protein gated Potassium channels | |||
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | ||||
| WikiPathways | Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | |||
| Potassium Channels | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Bepridil, an antiarrhythmic drug, opens mitochondrial KATP channels, blocks sarcolemmal KATP channels, and confers cardioprotection. J Pharmacol Exp Ther. 2006 Jan;316(1):182-8. | |||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.